Trial · NCT02656017
Results by group28
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 28
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in the Gastrointestinal Symptoms Rating Scale (GSRS) to 24 Months | Metformin | -0.04 | 95% Confidence Interval -0.18 to 0.10 | score on a scale | |
| Change in the Gastrointestinal Symptoms Rating Scale (GSRS) to 24 Months | Placebo | -0.11 | 95% Confidence Interval -0.24 to 0.03 | score on a scale | |
| Drug Tolerability | Metformin | 21 | Participants | ||
| Drug Tolerability | Placebo | 14 | Participants | ||
| Rate of Serious Adverse Events (SAE) | Metformin | 4 | Participants | ||
| Rate of Serious Adverse Events (SAE) | Placebo | 4 | Participants | ||
| Quality of Life Physical Component | Metformin | -0.11 | 95% Confidence Interval -1.69 to 1.46 | score on a scale | |
| Quality of Life Physical Component | Placebo | -0.51 | 95% Confidence Interval -2.05 to 1.03 | score on a scale | |
| Quality of Life Mental Component | Metformin | 1.01 | 95% Confidence Interval -1.23 to 3.25 | score on a scale | |
| Quality of Life Mental Component | Placebo | -0.11 | 95% Confidence Interval -2.29 to 2.08 | score on a scale | |
| Back Pain Frequency Over the Past 3 Months Since Last Visit | Metformin | 0.95 | 95% Confidence Interval 0.90 to 1.00 | odds ratio | |
| Back Pain Frequency Over the Past 3 Months Since Last Visit | Placebo | 0.92 | 95% Confidence Interval 0.88 to 0.98 | odds ratio | |
| Estimated Glomerular Filtration Rate (eGFR) | Metformin | -3.41 | 95% Confidence Interval -6.36 to -0.46 | ml/min/1.73m^2 | |
| Estimated Glomerular Filtration Rate (eGFR) | Placebo | -6.14 | 95% Confidence Interval -9.04 to -3.24 | ml/min/1.73m^2 | |
| Total Kidney Volume From Magnetic Resonance Imaging | Metformin | 3.87 | 95% Confidence Interval 1.09 to 6.74 | annual percent change | |
| Total Kidney Volume From Magnetic Resonance Imaging | Placebo | 2.16 | 95% Confidence Interval -0.52 to 4.91 | annual percent change | |
| Total Kidney Cyst Volume From Magnetic Resonance Imaging | Metformin | 9.37 | 95% Confidence Interval 3.82 to 15.22 | annual percent change | |
| Total Kidney Cyst Volume From Magnetic Resonance Imaging | Placebo | 5.36 | 95% Confidence Interval 0.13 to 10.86 | annual percent change | |
| Liver Volume From Magnetic Resonance Imaging | Metformin | 1.60 | 95% Confidence Interval 0.02 to 3.21 | annual percent change | |
| Liver Volume From Magnetic Resonance Imaging | Placebo | 1.21 | 95% Confidence Interval -0.32 to 2.77 | annual percent change |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02656017/results